MA54097A - Anticorps anti-fn14 humain - Google Patents

Anticorps anti-fn14 humain

Info

Publication number
MA54097A
MA54097A MA054097A MA54097A MA54097A MA 54097 A MA54097 A MA 54097A MA 054097 A MA054097 A MA 054097A MA 54097 A MA54097 A MA 54097A MA 54097 A MA54097 A MA 54097A
Authority
MA
Morocco
Prior art keywords
antibody
human anti
human
Prior art date
Application number
MA054097A
Other languages
English (en)
Inventor
Misato Ito
Risa Kashiwagi
Masakatsu Kawakami
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MA54097A publication Critical patent/MA54097A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA054097A 2018-10-31 2019-10-30 Anticorps anti-fn14 humain MA54097A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2018205995 2018-10-31

Publications (1)

Publication Number Publication Date
MA54097A true MA54097A (fr) 2022-02-09

Family

ID=70464144

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054097A MA54097A (fr) 2018-10-31 2019-10-30 Anticorps anti-fn14 humain

Country Status (20)

Country Link
US (1) US12209134B2 (fr)
EP (1) EP3875114A4 (fr)
JP (1) JP7415939B2 (fr)
KR (1) KR102922399B1 (fr)
CN (1) CN112930195B (fr)
AR (1) AR123671A1 (fr)
AU (1) AU2019369771B2 (fr)
BR (1) BR112021008424A2 (fr)
CA (1) CA3117930A1 (fr)
CO (1) CO2021005768A2 (fr)
IL (1) IL282650B2 (fr)
JO (2) JOP20210092A1 (fr)
MA (1) MA54097A (fr)
MX (1) MX2021004976A (fr)
MY (1) MY204672A (fr)
PH (1) PH12021550945A1 (fr)
SG (1) SG11202104463YA (fr)
TW (1) TWI843763B (fr)
WO (1) WO2020090892A1 (fr)
ZA (1) ZA202102879B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL282650B2 (en) * 2018-10-31 2024-09-01 Astellas Pharma Inc Anti-human fn14 antibody
AU2019402163A1 (en) 2018-12-20 2021-07-08 Kyowa Kirin Co., Ltd. Fn14 antibodies and uses thereof
KR20230131207A (ko) 2021-01-13 2023-09-12 아스텔라스세이야쿠 가부시키가이샤 ActRIIA, ActRIIB 및 Fn14에 결합하는 다중 특이성항체
WO2023062848A1 (fr) * 2021-10-14 2023-04-20 Astellas Pharma Inc. Composition pharmaceutique comprenant un anticorps fnl4 anti-humain ou un fragment de liaison à l'antigène de celui-ci pour la prévention ou le traitement du cancer
WO2024177972A2 (fr) * 2023-02-20 2024-08-29 The Wistar Institute Of Anatomy And Biology Chimères anticorps-cytokine

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
ES2213148T3 (es) 1993-03-11 2004-08-16 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Anticuerpo monoclonal dirigido contra el vih.
AU782067B2 (en) 1999-12-20 2005-06-30 Immunex Corporation TWEAK receptor
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
BRPI0608012A2 (pt) * 2005-03-07 2009-11-03 Genentech Inc método de tratamento de cáncer, método de aumento de atividade de célula nk, método de aumento de resposta ou atividade th1 inata, método de tratamento de uma disfunção mediada por th2, método de tratamento de uma doença imune, usos de uma molécula antagonista e uso de uma molécula agonista
DK1888113T3 (da) * 2005-05-27 2014-09-01 Biogen Idec Inc Tweak-bindende antistoffer
EP2545938A1 (fr) * 2007-08-03 2013-01-16 Abbott Biotherapeutics Corp. Utilisation thérapeutique dýanticorps de récepteur anti-TWEAK
AU2009246640A1 (en) 2008-05-15 2009-11-19 Biogen Idec Ma Inc. Anti-Fn14 antibodies and uses thereof
US8093006B2 (en) * 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
MY161302A (en) 2010-05-14 2017-04-14 Abbvie Inc IL-1 binding proteins
PE20131411A1 (es) 2010-10-05 2013-12-16 Hoffmann La Roche Anticuerpos contra la tweak humana y usos de los mismos
CO6680666A2 (es) 2010-10-05 2013-05-31 Hoffmann La Roche Anticuerpos contra la tweak humana y usos de los mismos
EP2683740B1 (fr) 2011-03-10 2018-07-04 Omeros Corporation Génération d'anticorps monoclonaux anti-fn14 par développement accéléré d'anticorps ex-vivo
PH12014500106A1 (en) 2011-08-02 2019-03-22 Astellas Pharma Inc Method for treating cancer by combined use of drugs
WO2013026099A1 (fr) 2011-08-23 2013-02-28 Transbio Ltd Protéines de liaison à fn14 et leurs utilisations
JP2016000003A (ja) * 2013-04-19 2016-01-07 アステラス製薬株式会社 新規抗ヒトｔｗｅａｋ抗体
AU2014280174A1 (en) 2013-06-14 2015-12-03 Bayer Pharma Aktiengesellschaft Anti-TWEAKR antibodies and uses thereof
US9238034B2 (en) * 2013-07-09 2016-01-19 The Translational Genomics Research Institute FN14 antagonists and therapeutic uses thereof
IL282650B2 (en) * 2018-10-31 2024-09-01 Astellas Pharma Inc Anti-human fn14 antibody

Also Published As

Publication number Publication date
CN112930195B (zh) 2024-03-19
AU2019369771A1 (en) 2021-06-03
IL282650B1 (en) 2024-05-01
MY204672A (en) 2024-09-09
EP3875114A4 (fr) 2022-08-10
PH12021550945A1 (en) 2022-03-28
AR123671A1 (es) 2023-01-04
BR112021008424A2 (pt) 2021-09-28
IL282650A (en) 2021-06-30
JOP20210093B1 (ar) 2024-12-22
EP3875114A1 (fr) 2021-09-08
US12209134B2 (en) 2025-01-28
JP7415939B2 (ja) 2024-01-17
IL282650B2 (en) 2024-09-01
MX2021004976A (es) 2021-06-15
CO2021005768A2 (es) 2021-05-10
SG11202104463YA (en) 2021-05-28
ZA202102879B (en) 2022-10-26
AU2019369771B2 (en) 2025-12-18
TWI843763B (zh) 2024-06-01
JOP20210093A1 (ar) 2023-01-30
TW202035459A (zh) 2020-10-01
US20210388096A1 (en) 2021-12-16
KR102922399B1 (ko) 2026-02-04
JOP20210092A1 (ar) 2021-04-29
CA3117930A1 (fr) 2020-05-07
KR20210084473A (ko) 2021-07-07
JPWO2020090892A1 (ja) 2021-09-24
CN112930195A (zh) 2021-06-08
WO2020090892A1 (fr) 2020-05-07

Similar Documents

Publication Publication Date Title
EP3903817A4 (fr) Nouvel anticorps anti-ccr8
EP3836960A4 (fr) Anticorps cd47 thérapeutiques
MA52884A (fr) Anticorps anti-il-11
MA53434A (fr) Anticorps anti-tigit
MA52366A (fr) Anticorps anti-tl1a optimisés
EP3883970A4 (fr) Anticorps anti-b7-h3
MA52212A (fr) Anticorps multivalent
EP3618865A4 (fr) Anticorps humain anti-sémaphorine 4d
MA47694A (fr) Anticorps anti-tigit
MA49034A (fr) Anticorps anti-lag3
MA44776A (fr) Anticorps anti-vista humain et leur utilisation
MA47268A (fr) Anticorps anti-gpc3
EP3841125A4 (fr) Anticorps monoclonaux contre tim-3 humain
MA52152A (fr) Anticorps
EP3837286A4 (fr) Anticorps dirigés contre znt8 humain
MA54097A (fr) Anticorps anti-fn14 humain
EP3617231A4 (fr) Anticorps anti-gpc-1
EP3831851A4 (fr) Anticorps anti-btla
IL284807A (en) Antibodies specific to human nectin-2
MA51134A (fr) Anticorps anti-alpha-synucléine
MA56466A (fr) Anticorps anti-epha4
MA51135A (fr) Anticorps anti-alpha-synucléine
EP3852779A4 (fr) Anticorps anti-klrg1
MA50654A (fr) Anticorps anti-pacap
MA49257A (fr) Anticorps anti-trkb